High Free Cash Flow Stocks
INCY is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
INCYTE CORP (INCY) Stock Price & Overview
NASDAQ:INCY • US45337C1027
Current stock price
96.91 USD
+1.64 (+1.72%)
At close:
97.4 USD
+0.49 (+0.51%)
After Hours:
The current stock price of INCY is 96.91 USD. Today INCY is up by 1.72%. In the past month the price increased by 1.02%. In the past year, price increased by 54.98%.
INCY Key Statistics
52-Week Range57.77 - 112.29
Current INCY stock price positioned within its 52-week range.
1-Month Range92.79 - 102.855
Current INCY stock price positioned within its 1-month range.
- Market Cap
- 19.286B
- P/E
- 13.03
- Fwd P/E
- 10.61
- EPS (TTM)
- 7.44
- Dividend Yield
- N/A
INCY Stock Performance
Today
+1.72%
1 Week
+2.39%
1 Month
+1.02%
3 Months
-3.16%
Longer-term
6 Months +3.67%
1 Year +54.98%
2 Years +67.69%
3 Years +57.45%
5 Years +15.67%
10 Years +14.81%
INCY Stock Chart
INCY Stock Screens
INCY currently appears in the following ChartMill screener lists.
Fastest Growing Stocks
INCY is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
CAN SLIM Stocks
INCY is part of our CAN SLIM stock list, indicating it is suited for high growth momentum investing and is a technical leader.
High EPS Growth Stocks
INCY occurs in our High EPS Growth Stocks screen list, indicating it is profitable, healthy and showing strong recent EPS growth.
INCY Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to INCY. When comparing the yearly performance of all stocks, INCY is one of the better performing stocks in the market, outperforming 81.04% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
INCY Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to INCY. INCY scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
INCY Earnings
On April 28, 2026 INCY reported an EPS of 1.81 and a revenue of 1.27B. The company beat EPS expectations (29.43% surprise) and beat revenue expectations (2.47% surprise).
Next Earnings DateJul 27, 2026
Last Earnings DateApr 28, 2026
PeriodQ1 / 2026
EPS Reported$1.81
Revenue Reported1.273B
EPS Surprise 29.43%
Revenue Surprise 2.47%
INCY Forecast & Estimates
33 analysts have analysed INCY and the average price target is 109.42 USD. This implies a price increase of 12.91% is expected in the next year compared to the current price of 96.91.
For the next year, analysts expect an EPS growth of 13.99% and a revenue growth 11.88% for INCY
Analysts
Analysts73.94
Price Target109.42 (12.91%)
EPS Next Y13.99%
Revenue Next Year11.88%
INCY Index Membership
INCY is currently included in the following stock indexes tracked on ChartMill.
INCY Financial Highlights
Over the last trailing twelve months INCY reported a non-GAAP Earnings per Share(EPS) of 7.44. The EPS increased by 304.35% compared to the year before.
Income Statements
Revenue(TTM)5.14B
Net Income(TTM)1.29B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.03% | ||
| ROA | 18.49% | ||
| ROE | 24.9% | ||
| Debt/Equity | 0.01 |
Chartmill High Growth Momentum
EPS Q2Q%56.03%
Sales Q2Q%20.87%
EPS 1Y (TTM)304.35%
Revenue 1Y (TTM)21.22%
INCY Ownership
Ownership
Inst Owners104.89%
Shares199.01M
Float194.97M
Ins Owners0.92%
Short Float %6.14%
Short Ratio7.77
INCY Industry Overview
INCY operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.8%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.1
INCY Latest News, Press Relases and Analysis
5 days ago - By: Chartmill
13 days ago - By: Chartmill
INCY Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INCY
Company Profile
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Company Info
IPO: 1993-12-06
INCYTE CORP
1801 Augustine Cut-Off
Wilmington DELAWARE 19803 US
CEO: Herve Hoppenot
Employees: 2844
Phone: 13026365400
INCYTE CORP / INCY FAQ
What does INCY do?
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
What is the stock price of INCYTE CORP today?
The current stock price of INCY is 96.91 USD. The price increased by 1.72% in the last trading session.
What is the dividend status of INCYTE CORP?
INCY does not pay a dividend.
What is the ChartMill rating of INCYTE CORP stock?
INCY has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Can you provide the sector and industry classification for INCYTE CORP?
INCYTE CORP (INCY) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of INCY stock?
INCYTE CORP (INCY) has a market capitalization of 19.29B USD. This makes INCY a Large Cap stock.
What is the Short Interest ratio of INCYTE CORP (INCY) stock?
The outstanding short interest for INCYTE CORP (INCY) is 6.14% of its float.